https://www.selleckchem.com/pr....oducts/bgb-15025.htm
Baseline [ F]-FDHT-PET in 21 patients detected 341 of 515 lesions found with standard imagingand 21 new lesions. Follow-up [ F]-FDHT-PET was evaluable in 17 patients with 349 lesions, showing a decrease in median SUV from 1.3 to 0.7 per-patient and lesion (P0.001). Median % reduction per-patient was -45%and per-lesion -39%. In patients with progressive disease (n=11), median % reduction was -30% versus -53% for patients who showed clinical benefit (in accordance with RECIST (n=3) or clinical evaluation (n=3); P=0.338). In this fea
Like
Comment
Share
